SCHEMBL5357809

SCHEMBL5357809

CC(C)c1cc(C=C2C(=O)Nc3ccc(CCCl)cc32)cc(C(C)C)c1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.71
ERBB2 P04626 2/20 0.71
PDGFRB P09619 2/20 0.71
IGF1R P08069 1/20 0.65
NOX4 Q9NPH5 1/20 0.65
LRRK2 Q5S007 6/20 0.50
RAF1 P04049 6/20 0.47
PSEN1 P49768 2/20 0.47
PSEN2 P49810 2/20 0.47
APH1B Q8WW43 2/20 0.47
NCSTN Q92542 2/20 0.47
APH1A Q96BI3 2/20 0.47
PSENEN Q9NZ42 2/20 0.47
MAP1LC3B Q9GZQ8 3/20 0.45
PLK4 O00444 2/20 0.45
PLK1 P53350 2/20 0.45
NTRK1 P04629 1/20 0.45
ARAF P10398 1/20 0.45
PIM1 P11309 1/20 0.45
BRAF P15056 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5368689 0.85 LRRK2 (0.69) EGFRERBB2PDGFRBLRRK2RAF1
SCHEMBL7136229 0.85 MAP1LC3B (0.57) EGFRERBB2PDGFRBNOX4LRRK2
SCHEMBL7133928 0.84 LRRK2 (0.53) EGFRERBB2PDGFRBLRRK2RAF1
SCHEMBL7139415 0.83 EGFR (0.60) EGFRERBB2PDGFRBIGF1RLRRK2
SCHEMBL5362863 0.83 ERBB2 (0.65) EGFRERBB2PDGFRBIGF1RLRRK2
SCHEMBL5358971 0.80 MAP1LC3B (0.70) EGFRLRRK2RAF1PSEN1PSEN2
SCHEMBL7137564 0.79 PSEN1 (0.52) PDGFRBLRRK2PSEN1PSEN2APH1B
SCHEMBL7133824 0.79 PSEN1 (0.52) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL7133366 0.79 NTRK1 (0.53) LRRK2RAF1PSEN1PSEN2APH1B
SCHEMBL5364476 0.79 ERBB2 (0.57) EGFRERBB2PDGFRBIGF1RLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK EGFR 286/4885ERBB2 19/4885PDGFRB 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.